AstraZeneca to offer MFN Medicaid prices and join TrumpRx site
AstraZeneca struck a deal with the White House to provide most‑favored‑nation pricing for Medicaid (and on new drugs), list its primary‑care medicines on the TrumpRx portal, and offer up to an 80% discount to eligible patients with chronic‑disease prescriptions. CMS says TrumpRx will not sell drugs directly while AstraZeneca says the site will enable reduced cash purchases; experts note Medicaid already has “best price” protections that may limit pharmacy‑counter impact, and AstraZeneca also pledged U.S. manufacturing and research investment — the second such agreement after Pfizer.
Corporate News
Economy
Health
Politics
📌 Key Facts
- CMS Administrator Mehmet Oz said AstraZeneca will provide 'most‑favored‑nation' (MFN) pricing to Medicaid patients and on new drugs, and will list 'all primary care medications' on the TrumpRx site.
- AstraZeneca said it will offer up to an 80% discount for eligible patients with prescriptions for chronic diseases.
- CMS says TrumpRx will not sell drugs directly, but AstraZeneca says the TrumpRx site will enable direct purchases from the company at a reduced cash price — the two accounts conflict.
- Experts note Medicaid already has 'best price' protections, suggesting the MFN offer may have limited impact at the pharmacy counter for many Medicaid patients.
- The deal follows President Trump's threats of 100% tariffs on pharmaceuticals unless drugmakers build U.S. plants; AstraZeneca announced plans to invest in U.S. manufacturing and research.
- This is the second such agreement in recent weeks, after Pfizer reached a similar deal to offer MFN rates and list drugs on TrumpRx.
📚 Contextual Background
- Medicaid is a government health insurance program for people with low incomes or disabilities and is funded jointly by state and federal governments.
- Medicaid spending is typically one of the largest components of U.S. state budgets.
📰 Sources (2)
Trump unveils deal for AstraZeneca to cut Medicaid drug prices and join "TrumpRx" site
New information:
- CMS Administrator Mehmet Oz said AstraZeneca will provide 'most‑favored‑nation' pricing to Medicaid patients and on new drugs, and list 'all primary care medications' on TrumpRx.
- AstraZeneca said it will offer up to an 80% discount for eligible patients with prescriptions for chronic diseases.
- TrumpRx will not sell drugs directly according to CMS, but AstraZeneca says the site will enable direct purchases from the company at a reduced cash price.
- Experts note Medicaid already has 'best price' protections, suggesting limited impact at the pharmacy counter for many Medicaid patients.
- Trump has threatened 100% tariffs on pharmaceuticals unless drugmakers build U.S. plants; AstraZeneca announced plans to invest in U.S. manufacturing and research.
- This is the second such deal in recent weeks, following Pfizer’s similar agreement to offer MFN rates and list drugs on TrumpRx.